Fulfilling the Promise of Medicine Together New FDA Safety Reporting Requirements 2010 John McLane, Ph.D. COO & Vice President Clinical and Regulatory.

Slides:



Advertisements
Similar presentations
Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Advertisements

Safety Reporting IN Clinical Trials
AEs, SAEs, and EAEs – An Overview
ADVERSE EVENT REPORTING
Pharmacovigilance Dr. Muiris Dowling,
Reporting Unanticipated Problems Involving Risk to Subjects or Others and Adverse Events WFUHS Policy/Procedure Effective Date 6/1/07 Wendy Murray Monitoring.
Update: 21 CFR PART 312 FDA Safety Reporting Requirements for INDs
Capturing and Reporting Adverse Events in Clinical Research
Director, Investigator Support & Integration Services, OCTRI
Pharmacovigilance Lindsey Connery Pharmacovigilance Manager, Cancer Research UK Clinical Trials Unit, Glasgow.
Pharmacovigilance and Risk Management Chapter 17.
IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.
Special Topics in IND Regulation
Vanderbilt Human Research Protections Program
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
Defining Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Paula Nicholson Research Facilitator
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Adverse Event Reporting Catherine Dillon.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
Paula Peyrani, MD Division of Infectious Diseases University of Louisville Performing the Study.
1 Nuts and Bolts of Safety Reporting The Role of the CRO Dr. Noa Lowenton Spier Pharma-Clinical S.A.G.
Using the short form and reporting adverse events Erin Coons, Senior IRB Specialist, COMIRB 1.
Reporting Unanticipated Problems and Adverse Events: A Change in Policy Mary A. Banks RN, BS, BSN Director, BUMC IRB Wednesday, November 14, 2007.
Unanticipated Problems Potentially Involving Risks to Subjects or Others Research Protections Office Serving UVM and FAHC Updated April 2012.
New Adverse Event Reporting Policy Effective September 1, 2007.
Development and Approval of Drugs and Devices EPI260 Lecture 9 May 23, 2012 Richard Chin, M.D.
Office of Research Oversight ORO Reporting Adverse Events in Research to ORO Paula Squire Waterman, MS, CIP Department of Veterans Affairs Office of Research.
H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.
EMORY INSTITUTIONAL REVIEW BOARD VERSION Unanticipated Problems, Protocol Deviations and Non-Compliance.
ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.
ICH V2 An FDA Update Susan Lu Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
Adverse Event/Unanticipated Problems Policy and Procedures November 2007.
AE/SAE/EAE Identification and Reporting AE/SAE/EAE Identification and Reporting.
Office of Research Oversight 1 VHA Handbook Research Compliance Reporting Requirements Revised May 21, 2010 (Presentation prepared for HRPP 101,
METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.
Adverse Event Reporting & SAE Reporting for Investigators Trial Number: (POLO-AML-2) Date of training:23 February 2013 Trainer: Deepa Sachdev Venue:Investigator.
EAE Training EAE Reporting and Assessment Overview DAIDS Regional Training Event, Regulatory Compliance Center Kampala, Uganda, September 2009 DAIDS Regional.
Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.
Serious Adverse Event Reporting Start-up Meeting March 25, 2010 Kingston, ON.
Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) SAR/SUSAR Mette Krag Dept. of Intensive Care 4131 Copenhagen University Hospital Rigshospitalet,
Role of Site Investigator Ensure subject safety is protected & well-managed Full compliance with requirements of Good Clinical Practice (GCP) Conduct the.
GEORGIA STATE UNIVERSITY IRB ADAPTED FROM DHHS GUIDANCE ON UNANTICIPATED PROBLEMS Unanticipated Problems.
D3 ) Not Recovered d5) Fatal Was a post-mortem undertaken?YesNo Was the SAE ongoing at time of death from other cause? Yes No d d m m y y y y d1) Recovered.
Main Line Hospitals Institutional Review Board Unanticipated Problems Anne Marie Hobson, BSN, JD, ORA Director Theresa Greaves, ORA Manager.
Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Unanticipated Problems 15 th FERCAP International Conference 24 Nov 15 Nagasaki, Japan.
Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
REPORTING ADVERSE EVENTS AND COMPLETING THE REPORT FORM
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Dartmouth Human Research Protection Program (HRPP) Data Safety Monitoring and Reporting requirements Brown Bag Series: Noon / First Tuesday of the Month.
Reportable Events Emory IRB 9/11/2014.
FHIR Adverse Event Resource
Assessing expectedness of an adverse event
Administering Informed Consent Issues for Discussion
Safety Reporting Nichol McBee, MPH, CCRP.
Expedited Adverse Event Reporting Requirements
Adverse Event Reporting: Trials and Tribulations
Remote Monitoring of Adverse Events
Pharmacovigilance in clinical trials
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Expedited Adverse Event Reporting Requirements
*Continue on SAE supplemental page CTT21 A if more space is required
Remote Monitoring of Adverse Events
Navigating Non-Compliance
SERIOUS ADVERSE EVENTS REPORTING
Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Ramy Abdelrahman, MD Division of Pediatric and Maternal Health (DPMH)
Dr Tim England TICH-2 SAE adjudicator
Presentation transcript:

Fulfilling the Promise of Medicine Together New FDA Safety Reporting Requirements 2010 John McLane, Ph.D. COO & Vice President Clinical and Regulatory Affairs Clinquest, Inc.

Fulfilling the Promise of Medicine Together 2 Safety Reporting Requirements Different requirements for Sponsors Investigators IRBs Different requirements depending on type of study and funding FDA Drug  IND vs Postmarketing Device Food Supplements Federal ICH

Fulfilling the Promise of Medicine Together 3 FDA: Sept 2010 Guidance for Industry And Investigators: Safety Reporting Requirements for INDs and BA/BE Studies New Regulations 21 CFR 312 IND Safety Reporting 21 CFR 320 BA/BE Studies Refers to Drugs and Biologicals Closer alignment to ICH/EMA requirements

Fulfilling the Promise of Medicine Together 4 Why New Regs and Guidances? Too many reports unfiltered SAE reports associated with Manifestations of the disease morbidity for stroke Common in study population Strokes in elderly population Study Endpoints Confusion with phrase: “associated with the use of the drug” and “reasonable possibility” Refine definitions

Fulfilling the Promise of Medicine Together 5 Define: Adverse Event (AE) Same as adverse experience Untoward medical occurrence associated with the use of a drug Whether or not considered drug related Note separation from causality Unfavorable or unintended sign or symptom Temporally associated with any use of the drug

Fulfilling the Promise of Medicine Together 6 Define: Suspected Adverse Reaction (SAR) Any AE reasonably possibility that drug caused AE Decreased level of certainty then an adverse reaction 1 st use of “reasonable possibility” The SAR & use of “reasonable possibility” is consistent with concepts about causality defined in ICH E2A

Fulfilling the Promise of Medicine Together 7 Define “reasonable possibility” Single occurrence of an uncommon event AE know to be associated with drug exposure Ex. Stevens-John syndrome 1 or more events not commonly associated with drug exposure Not common in the study population Aggregate analysis of events that occur more frequently in tx arm

Fulfilling the Promise of Medicine Together 8 Define: Unexpected AE or SAR Safety event: Not described in IB or protocol Event is of greater severity/specificity than previously described Hepato-necrosis is a Unexpected AE if IB has only hepatitus Event is described as seen in similar drugs (class effect) but not yet observed with this drug First occurrence of this type of event is a UAE

Fulfilling the Promise of Medicine Together 9 Define: Serious (SAE) Similar to prior use: Death Life-threatening Excludes AE or SAR that had it occurred in more serious form might have caused death In-patient hospitalization Prolongation of hospitalization Congenital anomaly/birth defect Refines the use of medical judgments by either investigator or sponsor

Fulfilling the Promise of Medicine Together 10 Safety Monitoring Sponsor Evaluate Safety of Drug for subjects Serious, Expectedness, Reasonable Possibility Analysis with other events related to drug use

Fulfilling the Promise of Medicine Together 11 Review of Safety Information Get safety information from all sources Domestic/foreign trials Foreign data to US: Safe Harbor Requirements Clinical epidemiology studies Annual literature review for safety Animal or in vitro expts. Report in safety reports ID all IND safety reports similar in nature previously reported Notify FDA and all “participating investigators” 15 day reports

Fulfilling the Promise of Medicine Together 12 SUSARS For the first time FDA recognizes SUSARs Three criteria Suspected adverse reaction Serious Unexpected Expedited IND safety report

Fulfilling the Promise of Medicine Together 13 Conclusion Move towards harmonization FDA will accept CIOMS I forms Use of SUSAR Clear definition Replace “associated with the use of the drug” with “reasonable possibility”

Fulfilling the Promise of Medicine Together 14

Fulfilling the Promise of Medicine Together 15 Relationship between AEs and UAPs The diagram illustrates three key points: The vast majority of adverse events occurring in human subjects are not unanticipated problems (area A) and do not need to be reported to the IRB. A small proportion of adverse events are unanticipated problems (area B) and need to be reported to the IRB. Unanticipated problems include other incidents, experiences, and outcomes that are not adverse events (area C) and need to be reported to the IRB.